BenevolentAI
target validation in colon tissue from ulcerative colitis patients in colonic mucosa biopsies from patients tissue samples treated with selective target inhibition showed comparable reduction of and to the positive controls validated as a target with a novel mechanism of action for ulcerative colitis an | BenevolentAI
Company
Deck Type
Sector
Industry
Deck date
January 2023
Slide
22 of 29
Similar slides by BenevolentAI
See diffirences between slides (animation)
Results
March 2023
ben potent activity in colon biopsies cross donor response summary inhibition release mean inhibition from donors fens | BenevolentAI
Investor Presentation
October 2022
target validation in colon tissue from ulcerative colitis patients in colonic mucosa biopsies from patients disease phenotype retained with high basal release and key mediators of pathology tissue samples treated with target selective tool compound ben positive controls and selective target inhibition showed comparable reduction of and to the positive controls validated as a target with a novel mechanism of action for ulcerative colitis | BenevolentAI
Investor Day
September 2022
target validation in colon tissue from ulcerative colitis patients in colonic mucosa biopsies from patients disease phenotype retained with high basal release and key mediators of pathology tissue samples treated with target selective tool compound ben positive controls and selective target inhibition showed comparable reduction of and to the positive controls validated as a target with a novel mechanism of action for ulcerative colitis | BenevolentAI
Related slides by other companies
Recursion Pharmaceuticals
Investor Day
January 2023
clinical target us patients diagnosed with cancer in in response tumor clearance alpha series achieves while minimizing peripheral inflammation | Recursion Pharmaceuticals
Recursion Pharmaceuticals
Investor Day
January 2023
clinical target us patients diagnosed with cancer in in response alpha series achieves tumor while minimizing peripheral inflammation | Recursion Pharmaceuticals
Equillium
Investor Presentation
November 2023
a first in class specific inhibitor aga | Equillium
Nuvectis Pharma
Investor Presentation
January 2024
mechanism of action | Nuvectis Pharma
Other recent decks by BenevolentAI
See all presentations (10 decks)
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Results
March 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io